Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Radiopharmaceuticals. Found 22 abstracts

no pagination
Miller MP, Kostakoglu L, Pryma D, Yu JQ, Chau A, Perlman E, Clarke B, Rosen D, Ward P. Reader training for the re-staging of biochemically recurrent prostate cancer using fluciclovine (18F) PET/CT. J Nucl Med. 2017 Oct;58(10):1596-602.
Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Mueller S, Schwartz LH, Zucca E, Fisher RI, Trotman J, Hoekstra OS, Hicks RJ, O'Doherty MJ, Hustinx R, Biggi A, Cavalli F, Lister TA, Cheson BD. Reply to B. Bennani-Baiti et al, H.J.A. Adams et al, E. Laffon et al, and E.A. Hawkes et al [Letter]. J Clin Oncol. 2015 Apr;33(10):1221-3.
Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Mueller S, Schwartz LH, Zucca E, Fisher RI, Trotman J, Hoekstra OS, Hicks RJ, O'Doherty MJ, Hustinx R, Biggi A, Cavalli F, Lister TA, Cheson BD. Reply to B. Bennani-Baiti et al, H.J.A. Adams et al, E. Laffon et al, and E.A. Hawkes et al. J Clin Oncol. 2015 Apr;33(10):1221-3.
Carlier T, Willowson KP, Fourkal E, Bailey DL, Doss M, Conti M. (90)Y -PET imaging: Exploring limitations and accuracy under conditions of low counts and high random fraction. Med Phys. 2015 Jul;42(7):4295-309.
Willowson KP, Tapner M, The QI, Bailey DL, Willowson KP, Tapner MJ, Ahmadzadehfar H, Amthauer H, Großer OS, Arbizu J, Martí-Climent JM, Rodriguez-Fraile M, Attarwala AA, Glatting G, Molina-Duran F, Bagni O, Filippi L, Benard F, Celler A, Bonutti F, Botta F, Ferrari M, Boucek JA, Francis R, Bourgeois AC, Bradley YC, Pasciak AS, Buchholz HG, Miederer M, Büsing KA, Schönberg SO, Carlier T, Eugene T, Cervo M, Moore SC, Civollani S, Pettinato C, Conti M, Craig AJ, Flux GD, Cremonesi M, D’Andrea M, Iaccarino G, Strigari L, D’Arienzo M, D’Asseler Y, Lambert B, Di Martino F, Doss M, Duan H, Hoffmann M, Flamen P, Vanderlinden B, Fletcher AM, Fourkal E, Freeman LM, Geatti O, Goedicke A, Habito CM, Ouyang J, Hallam A, Morgan DG, Heard S, Leek F, Holm S, Mortensen J, de Nijs R, Hooker CA, Jeans SP, Julyan PJ, Kabasakal L, Tanyildizi H, Tanyildizi H, Kappadath SC, Siman W, Lassmann M, Schlögl S, Law MW, Lee VH, Ng SC, Lhommel R, Lodge MA, Luster M, McGowan DR, McLamb B, Kaiser HJ, Mottaghy FM, Mulder RU, Judy P, Stone JR, Lopez A, Munk OL, Staanum PF, Muzaffar R, Osman MM, Nijran KS, Towey DJ, O’Keefe GJ, Pooley RA, McKinney JM, Rausch IF, Reindl M, Sheikh A, Song N, Srinivas SM, Weir G, Yu N, Bailey DL. A multicentre comparison of quantitative 90Y PET/CT for dosimetric purposes after radioembolization with resin microspheres: The QUEST Phantom Study. European Journal of Nuclear Medicine and Molecular Imaging. 2015 Jul;42(8):1202-22.   PMCID: 4480824
Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Mueller SP, Schwartz LH, Zucca E, Fisher RI, Trotman J, Hoekstra OS, Hicks RJ, O'Doherty MJ, Hustinx R, Biggi A, Cheson BD. Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. Journal of Clinical Oncology. 2014 Sep;32(27):3048-58.   PMCID: 5015423
Doss M. Addition of diagnostic CT scan does not increase the cancer risk in patients undergoing SPECT studies: comment on Brix et al.: radiation risk and protection of patients in clinical SPECT/CT [Comment]. Eur J Nucl Med Mol Imaging. 2014 May;41 Suppl 1:S146-7.
Klayton T, Li T, Yu JQ, Keller L, Cheng J, Cohen SJ, Meropol NJ, Scott W, Xu-Welliver M, Konski A. The role of qualitative and quantitative analysis of F18-FDG positron emission tomography in predicting pathologic response following chemoradiotherapy in patients with esophageal carcinoma. J Gastrointest Cancer. 2012 Dec;43(4):612-8.
Reddy S, Robinson MK. Immuno-positron emission tomography in cancer models. Semin Nucl Med. 2010 May;40(3):182-9.   PMCID: PMC2848398
Konski A, Li T, Sigurdson E, Cohen SJ, Small W, Spies S, Yu JQ, Wahl A, Stryker S, Meropol NJ. Use of molecular imaging to predict clinical outcome in patients with rectal cancer after preoperative chemotherapy and radiation. Int J Radiat Oncol Biol Phys. 2009 May;74(1):55-9.   PMCID: PMC2933375
Podoloff DA, Ball DW, Ben-Josef E, Benson AB, Cohen SJ, Coleman RE, Delbeke D, Ho M, Ilson DH, Kalemkerian GP, Lee RJ, Loeffler JS, Macapinlac HA, Morgan RJ, Siegel BA, Singhal S, Tyler DS, Wong RJ. NCCN task force: clinical utility of PET in a variety of tumor types. J Natl Compr Canc Netw. 2009 Jun;7 Suppl 2:S1-26.
Konski AA, Cheng JD, Goldberg M, Li T, Maurer A, Yu JQ, Haluszka O, Scott W, Meropol NJ, Cohen SJ, Freedman G, Weiner LM. Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma. Int J Radiat Oncol Biol Phys. 2007 Oct;69(2):358-63.
Chapman JD, Bradley JD, Eary JF, Haubner R, Larson SM, Michalski JM, Okunieff PG, Strauss HW, Ung YC, Welch MJ. Molecular (functional) imaging for radiotherapy applications: an RTOG symposium. Int J Radiat Oncol Biol Phys. 2003 Feb;55(2):294-301.
Chin R, McCain TW, Miller AA, Dunagan DP, Acostamadiedo J, Douglas Case L, Harkness BA, Adler LP, Haponik EF. Whole body FDG-PET for the evaluation and staging of small cell lung cancer: a preliminary study. Lung Cancer. 2002 Jul;37(1):1-6.
Kaminski JM, Nguyen K, Buyyounouski M, Pollack A. Prostate cancer gene therapy and the role of radiation. Cancer Treat Rev. 2002 Feb;28(1):49-64.
Scott WJ. Positron emission tomography (PET) and combined imaging modalities for staging lung cancer. Surg Clin North Am. 2002 Jun;82(3):477-95.
Uzzo RG, Novick AC, Goormastic M, Mascha E, Pohl M. Medical versus surgical management of atherosclerotic renal artery stenosis. Transplantation proceedings. 2002 Mar;34(2):723-5.
Adams GP, Weiner LM. Radioimmunotherapy of solid tumors: from fairytale to reality. Cancer Biother Radiopharm. 2001 Feb;16(1):9-11.
Chapman DJ. On measuring hypoxia in individual tumors with radiolabeled agents. Journal of Nuclear Medicine. 2001 Jan;42(11):1653-5.
Iyer RV, Haynes PT, Schneider RF, Movsas B, Chapman JD. Marking hypoxia in rat prostate carcinomas with beta-D-[125I]azomycin galactopyranoside and. J Nucl Med. 2001 Feb;42(2):337-44.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Radiopharmaceuticals

Radiopharmaceuticals radionuclide imaging diagnostic use Positron-Emission Tomography methods Fluorodeoxyglucose F18 X-Ray Computed Tomography therapy Human Emission-Computed Tomography Neoplasm Staging therapeutic use Neoplasms pathology radiotherapy Male Adenocarcinoma Lymphoma Treatment Outcome Animal Fludeoxyglucose F 18 Prognosis Multimodal Imaging pharmacokinetics Monoclonal Antibodies Female Radiation Dosage Emission-Computed Tomography-Single-Photon Antineoplastic Combined Chemotherapy Protocols Radioimmunodetection Prostatic Neoplasms instrumentation metabolism Lung Neoplasms Yttrium Radioisotopes Analysis of Variance Imaging Phantoms Combined Modality Therapy Esophageal Neoplasms Squamous Cell Carcinoma Cell Hypoxia drug therapy Comparative Study Adult Chemoradiotherapy Research Middle Aged Uremia Rats blood surgery prostate cancer radiography International Cooperation mortality Nonparametric Statistics Molecular Weight Non-Small-Cell Lung Carcinoma Microelectrodes Therapeutic Embolization Magnetic Resonance Imaging dosage Animal Disease Models Water Renal Artery X-Ray Computed Tomography Scanners Genetic Vectors Immunoglobulin Fragments Molecular Probe Techniques 1-amino-3-fluorocyclobutane-1-carboxylic acid Follow-Up Studies Technetium Tc 99m Pentetate Prospective Studies Anesthesia Neoplasm Antibodies Single-photon-emission computed tomography (imaging tumor hypoxia with radiolabeled agents) Radiotherapy Dosage Oximes Rectal Neoplasms Algorithms US Gov't Support-PHS X-Ray Microtomography Patient Care Planning Retrospective Studies Chimeric Proteins Drug Design review imaging tumor hypoxia radiopharmaceutical SPECT PET Cultured Tumor Cells Fluorouracil Predictive Value of Tests Neoplasm Transplantation immunology Oxygen Carcinoembryonic Antigen Image Enhancement administration & Photons analogs & Non-US Gov't Support Organotechnetium Compounds Renal Artery Obstruction Neoplasm Antigens Neoplasm Proteins Patient Selection Pathologic Neovascularization chemistry Computer-Assisted Radiotherapy Planning Mitomycin Biological Tumor Markers Disease-Free Survival Cell Surface Receptors utilization Aged Imaging (tumor trends Fluorine Radioisotopes Gene Transfer Techniques Deoxycytidine Oncology: GU Gene Therapy Mice Radiation Tolerance Neoplasm (solid Time Factors Esophagectomy Creatinine Iodine Radioisotopes analysis Arteriosclerosis Neoadjuvant Therapy adverse effects Nitroimidazoles Microspheres Hypoxia 18f-facbc derivatives Glucosides imaging tumor hypoxia with radiolabeled agents) ct classification Antibody Affinity Pet Positron-emission tomography Positron Emission Tomography Small Cell Carcinoma Antigen-Antibody Reactions Radioimmunotherapy
Last updated on Thursday, April 02, 2020